Aclarion, Inc. has established a commercial agreement with Weill Cornell Medicine to bring its Nociscan technology to Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. The agreement supports a clinical trial entitled "A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease," conducted under IRB Protocol No. 22-06024915. This study aims to investigate whether the dose and quantity of BMAC used for treating osteoarthritis and degenerative disc disease in the spine affects patient-reported functional outcomes and pain.
A subset of spine patients, selected per the clinical evaluation of Principal Investigator Jaspal Ricky Singh, MD, will be eligible for Nociscan. Dr. Singh, Vice Chair and Director of Interventional Spine at Weill Cornell Medicine and Rehabilitation Medicine Specialist at Och Spine, stated that their pioneering research into discogenic low back pain and concentrated bone marrow aspirate presents an ideal opportunity to utilize Nociscan's insights. The multidisciplinary spine team's comprehensive approach to treating spinal disorders includes physical therapy and various interventional techniques.
Chronic low back pain represents a significant global healthcare challenge, with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion's Nociscan solution is the first evidence-supported SaaS platform designed to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology objectively quantifies chemical biomarkers demonstrated to be associated with disc pain.
When used alongside other diagnostic tools, Nociscan can provide critical insights into the location of a patient's low back pain and has been shown to improve pain and function when all Nociscan-positive discs are treated. The platform operates through a cloud connection that receives magnetic resonance spectroscopy data from MRI machines for each lumbar disc being evaluated. Proprietary signal processing techniques then extract and quantify relevant chemical biomarkers, which are analyzed through algorithms to indicate whether a disc may be a source of pain.
This collaboration represents a significant step in integrating advanced diagnostic technology with cutting-edge therapeutic research. For more information about Aclarion and its technology, please visit https://www.aclarion.com. Additional details about the company's developments can be found at https://tinyurl.com/aconnewsroom. The integration of Nociscan into this clinical trial at a leading academic medical center may help validate the technology's role in optimizing treatment strategies for one of medicine's most prevalent and challenging conditions.
